Wegovy with Crohn's and Ozempic with Ulcerative Colitis: GLP-1 in IBD Evidence Review

Inflammatory bowel disease (IBD) — Crohn's disease and ulcerative colitis — and obesity are no longer opposites. Roughly 15–40% of adults with IBD now meet criteria for obesity (Dahiya 2022 nationwide US analysis^[4], Stein 2026 narrative review^[3]), and patients increasingly ask whether Wegovy, Ozempic, or Zepbound are safe with Crohn's or ulcerative colitis. The honest answer: the published evidence to date — including the Jan 2026 systematic review^[1] and the Nanah 2026 GLP-1-vs- bariatric comparison^[2] — suggests GLP-1 receptor agonists do not appear to worsen IBD disease activity in stable, well-controlled patients and do not interact pharmacologically with 5-ASA, biologics, or immunomodulators. They DO add a layer of overlapping GI side effects (nausea, diarrhea, abdominal pain) that can mimic or be misread as a flare, and they require careful timing around endoscopy and surgery. Active flare is not the time to initiate. Here is the verified evidence.

The honest summary

• Obesity is now common in IBD. Roughly 15–40% of US adults with Crohn's disease or ulcerative colitis meet obesity criteria; obese IBD patients have longer hospitalizations, more comorbidity, and higher healthcare utilization than normal-BMI peers (Dahiya 2022^[4], Stein 2026^[3]).
• No signal of IBD worsening on GLP-1 RAs to date. The Jan 2026 systematic review^[1] of GLP-1 receptor agonists in IBD reported clinically meaningful weight loss with no increase in IBD flares, hospitalizations, or escalations to advanced therapy in the included observational cohorts.
• Comparable outcomes vs bariatric surgery in obese IBD patients. Nanah 2026^[2] in Crohn's & Colitis 360 compared IBD-related outcomes in obese IBD patients receiving GLP-1 RAs vs bariatric surgery and found similar disease-activity trajectories — an important data point because bariatric surgery has historically been the only proven obesity intervention for this population.
• No pharmacokinetic interaction with 5-ASA, biologics, or immunomodulators. Mesalamine, azathioprine, methotrexate, infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, and upadacitinib have no published interaction with semaglutide or tirzepatide. Biologics are subcutaneous or IV and bypass the gut; oral immunomodulators are not known to be meaningfully affected by GLP-1-induced gastric-emptying delay.
• Overlapping GI side effects are the main clinical challenge. Wharton 2022^[10] documents nausea, diarrhea, abdominal pain, constipation, and vomiting as the dose-limiting toxicities of GLP-1 RAs — the exact symptom profile of an IBD flare. Without objective markers (fecal calprotectin, CRP, endoscopy) the two are indistinguishable from symptoms alone.
• Active flare is not the time to initiate. Most gastroenterologists prefer to defer GLP-1 initiation or dose escalation until disease is in clinical and biochemical remission.
• Endoscopy and surgery require extended hold. The AGA Rapid Clinical Practice Update on GLP-1 RAs prior to endoscopy (Hashash 2024^[6]) discusses individualized risk assessment; the ASA practice guidance recommends holding weekly GLP-1 agents at least one dose before elective procedures with general anesthesia. IBD patients undergo more endoscopy and surgery than the general population — this matters.
• Short bowel syndrome is a yellow flag. GLP-1 RAs slow gastric and small-bowel motility. Patients with short bowel syndrome from prior IBD resections rely on rapid transit for nutrient handling; adding a GLP-1 RA warrants gastroenterology and obesity-medicine co-management.

Why this question exists in 2026

Two epidemiologic curves crossed sometime in the 2010s. The prevalence of IBD in the US has roughly doubled in two decades (now ~3 million adults with Crohn's or ulcerative colitis), and the prevalence of obesity in adults has climbed past 40%. The result is that IBD is no longer a thin-patient disease — Dahiya 2022^[4] analyzed the US National Inpatient Sample and found that obesity was independently associated with longer length of stay and higher hospital charges in IBD admissions, even after adjusting for comorbidity. Stein 2026^[3] calls the combination a “double whammy” — obese IBD patients carry both the cardiometabolic burden of obesity AND the inflammatory and nutritional burden of IBD.

Until 2026 there was almost no published clinical-outcome data on GLP-1 receptor agonists in IBD patients, in part because the registration trials excluded most patients with active inflammatory bowel disease. That changed in early 2026 with the publication of the Jan systematic review^[1] in Obesity Pillars and the Nanah comparative-outcomes study^[2] in Crohn's & Colitis 360. The picture that emerged is reassuring but limited: in stable, well-controlled IBD patients (mostly on biologics, mostly in clinical remission at GLP-1 initiation), weight loss was meaningful and disease activity did not worsen across the follow-up windows reported. The data do NOT speak to GLP-1 RA use during active flare, in steroid-dependent patients, or in patients with severe short bowel from prior surgery.

The GI side-effect overlap: distinguishing a flare from a drug

The dose-limiting side effects of every FDA-approved GLP-1 receptor agonist are gastrointestinal. Pooled across STEP, SURMOUNT, SUSTAIN, and the broader literature (Wharton 2022 summary^[10]): nausea ~30–45%, diarrhea ~15–30%, constipation ~15–25%, vomiting ~10–20%, and abdominal pain ~10–20%. Severity is highest during initiation and dose escalation, most resolve over 4–12 weeks, and the discontinuation rate for GI intolerance is in the single digits per the registration trials.

Now overlay that on the symptom profile of a Crohn's or ulcerative colitis flare:

• Crohn's flare: abdominal pain, diarrhea, weight loss, fatigue, sometimes nausea.
• Ulcerative colitis flare: bloody diarrhea, urgency, tenesmus, abdominal cramping, fatigue.

The non-bloody overlap is substantial. A patient three weeks into Wegovy who reports nausea, mild diarrhea, and crampy lower-abdominal pain might be in the early dose-escalation phase of a GLP-1 RA, OR might be entering an IBD flare. Symptoms alone cannot reliably distinguish the two.

The practical disambiguation tools are objective markers and time course:

• Fecal calprotectin. A non-invasive stool test that rises with intestinal inflammation. A calprotectin in the normal range (typically <50–100 mcg/g depending on the lab) makes an active flare unlikely. A rising calprotectin in a patient on a stable GLP-1 dose argues for disease activity, not drug effect.
• Hematochezia or rectal bleeding. Not a documented GLP-1 RA side effect. Visible blood in stool should be treated as an IBD flare signal until proven otherwise.
• Time course. Nausea and diarrhea peaking 1–3 days after a dose increase and resolving before the next injection is a drug pattern. Steady or worsening symptoms across multiple doses is a disease pattern.
• CRP and other inflammatory markers. GLP-1 RAs do not raise CRP. A jump in CRP without another explanation favors a flare workup.

Delayed gastric emptying and IBD medication absorption

GLP-1 receptor agonists slow gastric emptying as a primary mechanism. That is a feature for satiety and glycemic control, and a complication for any orally administered medication that depends on rapid or predictable gastric delivery to the small intestine.

Most IBD therapies are not in that category:

• Subcutaneous and IV biologics — infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, golimumab, certolizumab — bypass the gut entirely. No interaction with GLP-1- induced gastric emptying delay.
• Oral 5-ASA (mesalamine, sulfasalazine, olsalazine, balsalazide). These are designed for delayed release in the distal small bowel or colon. The pH- or time-dependent coatings still function with slowed gastric emptying; no published clinical signal of altered efficacy when co-administered with GLP-1 RAs.
• Oral immunomodulators — azathioprine, 6-mercaptopurine, methotrexate. No published GLP-1 RA interaction. Methotrexate is often given parenterally in IBD anyway, bypassing the question.
• Oral small-molecule advanced therapies — tofacitinib, upadacitinib, ozanimod, etrasimod, filgotinib. These are absorbed across the small bowel. No clinically meaningful interaction with GLP-1 RAs published to date, but patients on these agents should report any new GI symptoms promptly.
• Corticosteroids (prednisone, budesonide, beclomethasone). Oral steroids are absorbed predictably even with slowed gastric emptying. Budesonide MMX (Uceris) and budesonide capsules (Entocort) use targeted-release formulations that are designed to survive gastric transit.

The Jan 2026 systematic review^[1] specifically noted no evidence of altered IBD-medication efficacy in the cohorts reviewed.

Disease activity monitoring during weight loss + GLP-1

The standard IBD monitoring stack does not change when a patient starts a GLP-1 RA, but the threshold for ordering objective markers should drop:

• Baseline. Document calprotectin, CRP, CBC, albumin, and current symptom severity (Harvey- Bradshaw Index for Crohn's, partial Mayo for ulcerative colitis) before starting any GLP-1 RA.
• Initiation and titration windows. If new GI symptoms appear during dose escalation, do not assume they are drug effects. Check calprotectin and CRP. If both are normal and symptoms are dose-temporally linked, drug toxicity is the likely explanation.
• Maintenance. Routine 6–12 month surveillance of calprotectin should continue at the patient's usual interval.
• Weight loss interpretation. Weight loss on a GLP-1 RA should be tracked against the trial benchmarks (semaglutide 14.9% at 68 weeks per STEP-1^[8]; tirzepatide 20.9% at 72 weeks per SURMOUNT-1^[9]). Rapid weight loss out of proportion to those expectations — especially with loss of muscle bulk, falling albumin, or new GI symptoms — should prompt a workup for active inflammation, malabsorption, or a non-GLP-1 cause.

The clinical caution: avoid escalation during an active flare

There is broad clinical consensus, even in the absence of randomized data, that GLP-1 receptor agonists should not be initiated or dose-escalated during an active IBD flare. Reasons:

• The drug's expected GI side effects will be indistinguishable from worsening flare symptoms, complicating both the patient's experience and the clinician's assessment.
• Volume depletion from flare-related diarrhea, combined with GLP-1 nausea and reduced oral intake, increases the risk of acute kidney injury — a documented (though uncommon) GLP-1 RA complication.
• Caloric restriction during a flare can compromise recovery; patients with active disease often need augmented protein and calorie intake, the opposite of what a GLP-1 RA produces.
• Steroid courses, biologic induction, and dose optimization should generally precede or follow GLP-1 initiation, not run in parallel.

The pragmatic rule: defer GLP-1 initiation until the patient has been in clinical and biochemical remission (normal calprotectin, normal CRP, formed stool) for at least 8–12 weeks. If a patient already on a stable GLP-1 dose enters a flare, most gastroenterologists pause further dose escalation and address the flare first; whether to hold the current dose entirely depends on severity and individual judgment.

Surgery in IBD on a GLP-1: extended pre-op hold considerations

IBD patients undergo more endoscopies and more abdominal surgeries than the average adult — surveillance colonoscopy, perianal exams under anesthesia, ileocolic resection for stricturing Crohn's, colectomy for steroid-refractory ulcerative colitis, ileal pouch-anal anastomosis. Every one of these involves either deep sedation or general anesthesia.

The AGA Rapid Clinical Practice Update (Hashash 2024^[6]) reviewed the pre-endoscopy GLP-1 RA question and concluded that the evidence does not support a blanket recommendation to hold these drugs for every patient before every procedure; an individualized risk assessment is recommended, accounting for symptom burden, dose, indication, and the type of procedure. The ASA practice guidance has separately recommended holding weekly GLP-1 RAs at least one dose before elective surgery with general anesthesia. The Fujino 2023 Cureus case report^[7] documents the underlying concern: retained gastric contents at induction despite standard fasting protocols, with risk of aspiration.

The IBD-specific layer: when ileocolic resection or colectomy is on the calendar, the surgical team should know the GLP-1 medication, the last-dose date, and the dose level. Most centers are converging on holding the weekly injection one to two doses before major elective abdominal surgery and resuming after the patient is tolerating an oral diet. For emergent surgery (toxic megacolon, perforation, obstruction) the anesthesia team manages aspiration risk with rapid-sequence induction regardless of GLP-1 status.

Short bowel syndrome and GLP-1: extra caution

A subset of long-standing Crohn's patients have had multiple ileal or ileocolic resections and meet the anatomic definition of short bowel syndrome (commonly, residual small-bowel length <200 cm). These patients depend on rapid intestinal transit and aggressive caloric absorption to maintain nutrition.

GLP-1 receptor agonists slow gastric emptying and reduce appetite — both of which are problematic in short bowel:

• Reduced caloric intake can worsen the malnutrition that short-bowel patients already work to prevent.
• Slowed gastric emptying delays the delivery of nutrients to whatever small bowel remains, and may compound medication-absorption uncertainty.
• A separate GLP-1 analog, teduglutide (a GLP-2 RA, not GLP-1), is actually FDA-approved for short bowel syndrome — the receptor biology is different and should not be confused with the weight-loss GLP-1 RA class.

The Jan 2026 systematic review^[1] did not include enough short-bowel patients to characterize outcomes. The default position should be: GLP-1 RA use in short bowel syndrome is off the standard pathway and requires gastroenterology, surgery, and obesity-medicine co-management before initiation.

Patient action plan

For a patient with stable Crohn's disease or ulcerative colitis considering a GLP-1 RA:

1. Confirm remission status with the gastroenterologist. Recent calprotectin, recent CRP, and current symptom score (Harvey-Bradshaw or partial Mayo) before starting.
2. Coordinate prescribing. Either obesity-medicine or the gastroenterologist can write the prescription, but the other should know. Communication is the failure mode.
3. Plan endoscopy timing. If a surveillance colonoscopy is due in the next 3–6 months, build the GLP-1 hold window into the procedure planning from the start.
4. Build a symptom decision rule. New nausea or mild diarrhea within 3 days of a dose increase that resolves before the next injection is most likely drug. New bloody diarrhea, urgency, persistent abdominal pain across multiple doses, fever, or unintended weight loss out of proportion to expected trajectory is a flare workup, not a drug-tolerance issue.
5. Maintain protein and hydration. The Wharton 2022 GI side-effect playbook^[10] (small frequent meals, low-fat protein-first, slow eating, electrolyte fluids) is especially important in IBD patients, who tend toward both micronutrient deficiencies and dehydration.
6. Continue IBD therapy unchanged. Biologic, 5-ASA, and immunomodulator doses should not be modified to accommodate the GLP-1 RA in the absence of a specific interaction or adverse event.

Magnitude context: weight loss vs IBD-relevant outcomes

Bottom line

• Stable, well-controlled Crohn's disease or ulcerative colitis does not appear to be a contraindication to a GLP-1 receptor agonist based on currently published data (Jan 2026 systematic review^[1], Nanah 2026 GLP-1-vs-bariatric comparison^[2]).
• 5-ASA, biologics, oral immunomodulators, and oral small-molecule advanced therapies have no published interaction with semaglutide or tirzepatide.
• The GI side-effect overlap is real. Objective markers (calprotectin, CRP) and time course separate drug tolerability from disease activity. Symptoms alone do not.
• Active flare is a reason to defer initiation or dose escalation, not necessarily to stop a stable existing dose.
• Endoscopy and surgery require coordinated GLP-1 hold planning. IBD patients undergo more procedures than the average adult; this matters more for this population.
• Short bowel syndrome from prior IBD resection is a yellow flag and requires multidisciplinary input before starting a GLP-1 RA.
• The decision belongs to a coordinated obesity-medicine + gastroenterology team, not to either alone.

Related research and tools

• Does Wegovy cause ileus or bowel obstruction? — the FDA 2023 label change, FAERS post-marketing reports, and how to recognize obstruction versus ordinary GLP-1 nausea
• Does diarrhea cause weight loss? — the IBD section overlaps directly with this article's symptom-disambiguation framework
• GLP-1 side-effect questions answered — the master Q&A hub for nausea, diarrhea, constipation, abdominal pain, and dose escalation
• What to eat on a GLP-1: the protein-first guide — the meal-pattern playbook, especially relevant for IBD patients who already work hard to maintain adequate protein and micronutrients
• GLP-1 protein calculator — calculate your daily protein target (1.6–2.0 g/kg) to preserve lean mass during GLP-1 weight loss
• GLP-1 side-effect timeline tool — expected onset and resolution windows for each GI symptom by trial week
• Wegovy, Ozempic, Zepbound, Mounjaro — the FDA label and trial pages for each agent in question

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about whether to start, continue, hold, or stop a GLP-1 receptor agonist in a patient with Crohn's disease or ulcerative colitis must be made by the treating gastroenterologist and obesity-medicine clinician based on individual disease activity, surgical history, nutritional status, and concurrent therapy. New or worsening symptoms on a GLP-1 RA in an IBD patient should prompt prompt clinician contact — do not attempt to push through dose escalation in the face of bloody diarrhea, persistent abdominal pain, fever, or unintentional weight loss out of proportion to expected trajectory. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. The IBD-specific evidence base is young; expect this article to be updated as longer-duration cohort and randomized data are published.

Last verified: 2026-05-28. Next review: every 6 months given the rapidly evolving IBD + GLP-1 evidence base, or sooner if a major society guideline or randomized trial reports.